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Genome-wide association analyses identify two
susceptibility loci for pachychoroid disease central
serous chorioretinopathy
Yoshikatsu Hosoda et al.#
The recently emerged pachychoroid concept has changed the understanding of age-related
macular degeneration (AMD), which is a major cause of blindness; recent studies attributed
AMD in part to pachychoroid disease central serous chorioretinopathy (CSC), suggesting the
importance of elucidating the CSC pathogenesis. Our large genome-wide association study
followed by validation studies in three independent Japanese and European cohorts, con-
sisting of 1546 CSC samples and 13,029 controls, identified two novel CSC susceptibility loci:
TNFRSF10A-LOC389641 and near GATA5 (rs13278062, odds ratio= 1.35, P= 1.26 × 10−13;
rs6061548, odds ratio= 1.63, P= 5.36 × 10−15). A T allele at TNFRSF10A-LOC389641
rs13278062, a risk allele for CSC, is known to be a risk allele for AMD. This study not
only identified new susceptibility genes for CSC, but also improves the understanding of the
pathogenesis of AMD.
https://doi.org/10.1038/s42003-019-0712-z OPEN
#A full list of authors and their affiliations appears at the end of the paper.
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Central serous chorioretinopathy (CSC) is a common eyedisease characterized by serous retinal detachment of themacular regions and retinal pigment epithelium (RPE)1,2.
Although retinal detachments in CSC eyes typically resolve
spontaneously, some cases become chronic resulting in permanent
retinal tissue damage3–5. Additionally, recent studies have shown
that the occurrence of choroidal neovascularization (CNV) is a
common complication, leading to severe vision loss6,7. Based on
these findings, CSC is currently recognized as an important sight-
threatening disease that can lead to legal blindness. Although
clinical studies have shown that dysfunction of the retinal pigment
epithelium and hyperpermeability of the choroidal vessels are
essential in the etiology of CSC8, the exact mechanisms underlying
CSC pathology remain unknown. Previous studies reported that
the risk factors of CSC include glucocorticoid use, increased
adrenergic hormones, stress, male gender, Helicobacter pylori
infection, and type A personality1,5,9–16.
Recently, the pathological overlap between age-related macular
degeneration (AMD), which is a major cause of legal blindness in
developed countries, and CSC has received increased attention as
they share similar clinical characteristics, including serous retinal
detachment, pigment epithelium detachment, and CNV occur-
rence. Particularly, because CNV secondary to CSC (which was
recently named as pachychoroid neovasculopathy because of its
characteristic thick choroid17–19) often masquerades as AMD20,
recent studies highlighted the importance of differentiating AMD
and CSC18,19,21–25. Interestingly, although AMD and CSC show
similar clinical manifestations, genetic studies revealed that they
have contrasting characteristics with respect to complement factor
H (CFH), an established AMD susceptibility gene26; the risk alleles
for AMD at CFH Y402H and CFH I62V confer a protective effect
against CSC27–29. Taken together, investigating the genetic back-
ground of CSC is currently of great importance and can improve
the understanding of the etiology of both CSC and AMD.
Two genome-wide association studies (GWASs) for CSC have
been reported30,31. However, both studies have limitations such
as a lack of replication studies using independent cohorts and
limited sample sizes. Even after considering previous candidate
gene studies28,32–34, no CSC susceptibility gene other than CFH
has been well-replicated and established. Therefore, robust
GWASs are needed to further understand the genetic background
of CSC.
In the present study, we conducted a large-scale GWAS for
CSC followed by replication analyses using three independent
Japanese and European cohorts. Our analysis using 1546 CSC
cases and 13,029 controls identified two novel CSC susceptible
loci, rs13278062 at TNFRSF10A-LOC389641 and rs6061548 near
GATA5, which were significantly associated with the disease on a
genome-wide scale. As these single-nucleotide polymorphisms
(SNPs) showed a robust and homogenous effect among the
Japanese and European cohorts, they may be important targets
for further molecular biological evaluation and the development
of new treatments.
Results
GWAS for CSC and replication analyses in Japanese cohorts.
After stringent quality control, 2,893,743 SNPs were included in
the first-stage of the GWAS in a Japanese case–control cohort
consisting of 610 CSC patients and 2850 controls. We included
three principal components as covariates to adjust for possible
population stratification, which provided an acceptable control;
the genomic inflation factor lambda (λGC) was 1.157. The
quantile–quantile plot is shown in Supplementary Fig. 1.
To examine whether a population substructure existed and its
influence on the GWAS results, we performed principal compo-
nent analysis (PCA) for the current study using publicly available
multiethnic genotype data from 1000 Genome project (Phase 3,
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/) (Sup-
plementary Fig. 2) and without this data (Supplementary Fig. 3).
The analyses revealed that nearly all subjects in our discovery
GWAS fell into the Japanese cluster, whereas a mild population
substructure existed within the current discovery GWAS.
In the first-stage, we identified two loci showing a suggestive
P-value of <1.0 × 10−6 for rs13278062 at TNFRSF10A-LOC389641
(ORdiscovery= 1.38, Pdiscovery= 5.94 × 10−7) and rs6061548 near
GATA5 (ORdiscovery= 1.61, Pdiscovery= 2.52 × 10−7). The Manhat-
tan plot, regional plots and linkage disequilibrium plots are
shown in Figs. 1 and 2 and Supplementary Fig. 4, respectively.
Downstream of rs13278062, some SNPs in the CHMP7 region
showed relatively low P-values.
No variants were observed downstream of rs6061548 in the
regional plot probably owing to stringent QC. Therefore, we
made a regional plot around rs6061548 using the GWAS results
before QC was applied. In this regional plot, many SNPs within
GATA5 showed low P-values; the most significant association
was found at rs13044490 within GATA5 (OR= 1.67, P= 2.94 ×
10−10, Supplementary Fig. 5).
Fig. 1 Manhattan plot for discovery GWAS using 610 patients with central serous chorioretinopathy and 2580 control participants. Each plot shows
−log10-transformed P-values for all SNPs. The horizontal solid line represents the genome-wide significance threshold of P= 5.0 × 10−8, and the lower
broken line represents the suggestive threshold of P= 1.0 × 10−6. Two SNPs exceeded the suggestive threshold; rs13278062 at TNFRSF10A-LOC389641
(P= 5.94 × 10−7) and rs6061548 near GATA5 (P= 2.52 × 10−7).
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In the replication stage using 278 independent CSC samples
from Japan, both rs13278062 at TNFRSF10A-LOC389641 (OR=
1.35, P= 8.97 × 10−4) and rs6061548 near GATA5 (OR= 1.39,
P= 1.28 × 10−2) showed significant associations with CSC
(Table 1).
The associations of two SNPs with CSC were further evaluated
in another Japanese CSC case–control dataset. Using the data
from Kobe University Hospital, we found that rs6061548 near
GATA5 was also significantly associated with CSC in this dataset
(OR= 2.29, P= 3.26 × 10−6). Rs13278062 showed a trend
towards an association with the same direction of effect (OR=
1.19, P= 0.189, Table 1).
Replication in a European cohort and meta-analysis. We con-
ducted trans-ethnic replication analyses to confirm the association.
Association analysis using 521 cases and 3577 controls of European
descent revealed that rs13278062 and rs6061548 were significantly
associated with CSC in the European cohort (Table 1). The odds
ratios of the SNPs in the European cohort were similar to that
observed in the Japanese cohort (OREuropean= 1.36, PEuropean=
1.47 × 10−5 for rs13278062, and OREuropean= 1.60, PEuropean=
5.80 × 10−4 for rs6061548). A meta-analysis of the Japanese and
European cohorts also revealed strong association between CSC
and rs13278062 at TNFRSF10A-LOC389641 (ORmeta-all= 1.35,
Pmeta-all= 1.26 × 10−13), as well as rs6061548 near GATA5
(ORmeta-all= 1.63, Pmeta-all= 5.36 × 10−13). As shown in Fig. 3, the
effects of rs13278062 and rs6061548 on CSC occurrence were
homogenous among the Japanese and European cohorts.
Association of previously reported SNPs with CSC. Previous
GWAS of CSC reported two susceptibility loci, CFH rs1329428
and SLC7A5 rs1186504930,31. In the current GWAS, CFH
rs1329428 showed a significant association with CSC (OR= 1.17,
P= 0.015). SLC7A5 rs11865049 showed the same direction of
effect as previously reported but did not reach a significant value
(OR= 1.15, P= 0.24). These results are summarized in Table 2.
Expression in human tissue. A search in a publicly available
quantitative trait locus analysis (eQTL) database revealed that
rs13278062 was significantly associated with TNFRSF10A
expression (GTEx Portal. https://gtexportal.org/home/), but not
with any other genes nor CHMP7. A multi-tissue eQTL plot
revealed that the normalized effect size (NES) of rs13278062
on TNFRSF10A expression was strongest in the adrenal
gland (NES=−0.973, P= 4.5 × 10−39; Supplementary Fig. 6).
Although it was unclear whether rs6061548 near GATA5 affects
the expression or function of any genes in the database,
rs13044490 within GATA5, which was a top-hit SNP in the
regional plot, was significantly associated with GATA5 expres-
sion. The effect of rs13044490 on GATA5 expression was stron-
gest in the esophageal muscularis (NES= 0.347, P= 3.9 × 10−8;
Supplementary Fig. 7).
To confirm the expression of the genes in the human retina
and choroid that play a role in CSC pathogenesis, we conducted
database searching using the Eyeintegration database (https://
eyeintegration.nei.nih.gov/, v1.01) and The Ocular Tissue Data-
base (https://genome.uiowa.edu/otdb/), the only databases that
includes gene expression data in human retina and choroid. The
Eyeintegration database showed that the expression of both
TNFRSF10A and GATA5 in the adult human RPE/choroid (n=
48) was stronger than that in the adult human retina (n= 52) as
summarized in Fig. 4. These results were supported by The
Ocular Tissue Database, which shows that the expression of
TNFRSF10A in the adult human RPE/choroid was stronger than
that in the adult human retina (PLIER normalized expression
level= 18.90 vs. 16.34) and that of GATA5 in the adult human
RPE/choroid was also stronger than that in the adult human
retina (PLIER normalized expression level= 57.26 vs. 48.30). The
Eyeintegration database revealed that the expression of both
TNFRSF10A and GATA5 was also observed in other human
tissues (Supplementary Note).
Pathway analysis. We performed pathway analysis using
VEGAS2Pathway (https://vegas2.qimrberghofer.edu.au/). In total,
9723 pathways were evaluated. The top ten pathways are shown
in Supplementary Table 1. The most significantly associated
pathway was the ESCRT-III complex (M00412, P= 2.60 × 10−5).
However, no pathways reached the genome-wide, pathway-based
significant P-value of <1.0 × 10−530,35.
Discussion
In the current study, we identified two novel susceptible loci,
rs13278062 at TNFRSF10A-LOC389641 and rs6061548 near
GATA5 for a common pachychoroid disease, CSC, through a
large GWAS followed by replication studies in three independent
case–control datasets of Japanese and European origin. These
SNPs showed robust and consistent association among all data-
sets. Interestingly, rs13278062 has been reported to be a sus-
ceptibility SNP for AMD. As the relationship between AMD and
CSC has received increased attention, the current results have
Fig. 2 Regional association plots of evaluated SNPs around two
suggestive SNPs in discovery GWAS. Plots represent the −log10
(P-values) obtained from the first-stage GWAS. Each plot corresponds
to the following; a TNFRSF10A-LOC389641 and b near GATA5 regions.
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important scientific implications that improve the understanding
of the similarities and differences between AMD and CSC.
TNFRSF10A was first identified as an AMD susceptibility locus
in a Japanese population36. Although this association has been
confirmed in other ethnicities, the effect of TNFRSF10A on AMD
in Caucasians was reported to be weaker than that in Asian
population37–39. Recently, some researchers reported a subgroup
within AMD that incorporates the characteristics of CSC, such as
thick choroid and choroidal vascular hyperpermeability7,17,19.
Although the precise rate of the subgroup among patients with
AMD is currently unknown, the rate is estimated to be higher in
Asians than in Caucasians22,40. Taken together with the current
result, we speculate that eyes with CNV, which is traditionally
diagnosed as AMD, include CNV secondary to CSC, which may
occur more frequently in Asians compared to that Caucasians. In
support of this, the effect of TNFRSF10A on CSC occurrence
Fig. 3 Forest plots showing the effects of novel susceptibility SNPs in each cohort and meta-analysis. Forest plots showing the effects of a rs13278062
and b rs6061548 on CSC in each cohort and meta-analysis. Both SNPs showed robust, consistent, and mild to moderate association with CSC across
ethnic groups.
Fig. 4 Boxplots of TNFRSF10A and GATA5 expression levels in the human retina and RPE/choroid. Expression levels of TNFRSF10A and GATA5 in the
human retina (n= 52) and RPE/choroid (n= 48) are given in transcripts per million (TPM). TNFRSF10A was strongly expressed in the human RPE/choroid
compared to in the retina (116.62 ± 58.53 vs. 18.11 ± 8.96 TPM, P < 0.001). GATA5 was also strongly expressed in the human RPE/choroid compared to in
the retina (69.05 ± 37.91 vs. 4.66 ± 7.08 TPM, P < 0.001). TPM values are expressed as the mean ± standard deviation and compared by Wilcoxon test.
RPE retinal pigment epithelium.
Table 2 Association of previously reported SNPs on GWAS study with CSC.




OR (95% CI) P* Effect directions as
reported
rs1329428 CFH 1 196702810 T 0.506 0.466 1.17 (1.03–1.32) 1.45 × 10−2 +
rs11865049 SLC7A5 16 87874140 A 0.078 0.069 1.15 (0.91–1.44) 0.24 +
CHR chromosome, EAF effect allele frequency in the discovery stage, CSC central serous chorioretinopathy, OR odds ratio, CI confidence interval
*P-values were derived using logistic regression analysis
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(OR= 1.38) in the present study was higher than that of tradi-
tional AMD occurrence in a previous study (ORforAMD= 1.25 in
Asian, and ORforAMD= 1.11 in European)39. It is also possible
that TNFRSF10A has pleiotropic effects on both AMD and CSC.
The effects of TNFRSF10A on AMD should be further evaluated
while stratifying the data for the presence of a pachychoroid
background.
CNV accompanied by the characteristics of CSC was recently
termed as pachychoroid neovasculopathy, as the thickened
choroid is the most characteristic clinical feature of the condition.
Gene expression evaluation in ocular tissue supports the impor-
tance of the RPE/choroid regarding the etiology of pachychoroid
neovasculopathy and CSC, as TNFRSF10A is more strongly
expressed in the RPE/choroid than in the retina. However, the
exact role of TNFRSF10A in CSC occurrence or choroidal
structure is unclear. Considering that the adrenergic hormones
are established risk factors for CSC41,42, and that the eQTL
showed that the genotype of rs13278062 at TNFRSF10A was
strongly associated with its expression in the adrenal gland,
TNFRSF10A may affect the risk of CSC by modulating hormone
secretion from the adrenal glands.
We additionally identified that rs6061548 near GATA5 was
associated with CSC. GATA5 is known to play an important role
in vascular system development43–45. A recent study showed that
GATA5 is expressed in the microvascular endothelial cells and that
its inactivation in mice results in vascular endothelial dysfunc-
tion46. Considering the stronger expression of GATA5 in the RPE/
choroid than in the retina, we speculate that GATA5 may affects
the susceptibility to CSC through vascular endothelial dysfunction
in the choriocapillaris, which constitutes the inner vascular layers
of the choroid, composed largely of fenestrated capillaries. This
hypothesis is compatible with previous reports showing that eyes
with CSC had choriocapillary hypoperfusion47,48, and primary
choroidal ischemia48. GATA5 is also known to play an important
role in stomach development and gastric diseases49–51. Interest-
ingly, GATA5 is reported to be upregulated by H. pylori infec-
tion52, which is one of the risk factors of CSC10,12–14. As described
above, GATA5 may also be an important target for the further
understandings of CSC.
The current study has many strengths and limitations. The
main strengths are its large sample size and that multiple repli-
cation studies were performed in different ethnic groups, which
led to robust results. As CSC is thought to be a benign, self-
limiting disease, its genetic background has not been clarified.
However, the pathology of CSC has become an important issue in
relation to AMD. To our knowledge, this study is the largest
genetic study on CSC and the first study to identify transethni-
cally robust susceptible genes using a non-hypothesis-driven,
exploratory approach. Considering the identification of relatively
high, consistent effects across multiple ethnic groups, the current
study has strong scientific implications. However, the sample size
of this study was still limited. An even larger sample size is
required to identify additional susceptibility SNPs with low allele
frequency or low effect size and to further elucidate disease
pathways in CSC. Another limitation is the inflated λGC in our
discovery GWAS, which may have led to false-positive associa-
tions. This inflation may be related to the presence of a mild
population substructure, as inflation was still observed even after
conducting the GWAS using samples genotyped with a single-
DNA microarray platform, OmniExpress (λGC= 1.098). How-
ever, the positive associations of both TNFRSF10A-LOC389641
rs13278062 and near GATA5 rs6061548 were still significant even
after genomic control correction (Pmeta= 2.57 × 10−12 and
Pmeta= 6.29 × 10−12, respectively; Supplementary Table 2), and
thus these associations appear to be robust.
In summary, we identified two novel CSC susceptibility loci,
rs13278062 at TNFRSF10A-LOC389641 and rs6061548 near
GATA5, using a total of 1546 CSC cases and 13,029 controls.
These variants showed robust, consistent, and mild to moderate
associations with CSC across ethnicities. We confirmed that both
genes are expressed in the choroid, which is the main focus of
CSC and AMD. Our findings improve the understanding of the
pathogenesis of CSC and AMD.
Methods
Patient enrollment. In the discovery GWAS, 610 Japanese patients with CSC were
recruited from the Kyoto University Hospital, and 2850 healthy Japanese controls
were recruited from the Aichi Cancer Center Research Institute, Hayashi Eye
Hospital, Mizoguchi Eye Hospital, Oita University Faculty of Medicine, Ideta Eye
Hospital, Shinjo Eye Clinic, Miyata Eye Hospital, Ozaki Eye Hospital, Kyoto
University Hospital, and Nagahama City Hospital. Detailed information of the
control cohort is described elsewhere53, and is briefly summarized in the Supple-
mentary Note and Supplementary Table 3.
In the first replication stage, 278 CSC patients were recruited from across Japan,
particularly Kyoto University Hospital (N= 57), Kagawa University Hospital (N=
104), Yamanashi University Hospital (N= 80), and Fukushima Medical University
Hospital (N= 37). Control allele frequency data were extracted from the genome-
wide dataset of healthy Japanese subjects from the Tohoku Medical Megabank
Organization (N= 3498)54–56, Kyoto University (N= 3074)57,58, and Yokohama
City University dataset (N= 1048). Detailed information is shown in
the Supplementary Note. In the second and the third replication stages, the Kobe
CSC case–control dataset, which consists of 137 Japanese patients with CSC and
1153 Japanese controls, and European CSC case–control dataset, which consists of
521 European patients with CSC and 3577 European controls, were utilized,
respectively. Although the detailed information for this dataset has been described
previously30,31, a brief summary is also provided in the Supplementary Note.
All procedures adhered to the tenets of the Declaration of Helsinki. The
Institutional Review Board and Ethics Committee of each participating institute
approved the respective study protocols. All patients were fully informed of the
purpose and procedures of the study, and written consent was obtained from all
patients prior to their participation in the study.
Diagnosis of patients with CSC. All patients underwent a comprehensive oph-
thalmic examination, including visual acuity measurement; slit-lamp biomicro-
scopy; dilated fundoscopy; color fundus photography; and optical coherence
tomography (OCT) examination, including enhanced depth imaging, fundus
autofluorescence, fluorescein angiography, and indocyanine green angiography
CSC was diagnosed based on medical history, serous retinal detachment, thickened
choroid with dilated choroidal vessels seen on OCT, choroidal vascular hyper-
permeability on ndocyanine green angiography, and/or leakages on fluorescein
angiography at the level of the RPE. Based on these findings, two retina specialists
(M.M. and Y.H.) diagnosed the patients independently, and discrepancies were
adjusted in a face-to-face consensus session. Patients with other causes of fluor-
escein leakage or serous retinal detachment unrelated to CSC (e.g., AMD, intrao-
cular inflammation, diabetic retinopathy, or retinal vein occlusion) were excluded
from the study. In the second and third replication stages, patients with CSC were
diagnosed based on previously described criteria29–31. The details are summarized
in the Supplementary Note.
Genotyping. Genomic DNA was extracted from peripheral blood samples
according to standard laboratory procedures. A series of BeadChip DNA arrays
(Illumina, San Diego, CA, USA), namely OmniExpress (N= 250) and Asian
Screening Array (N= 360), were used for genotyping the CSC samples, while
Human610-Quad BeatChip (N= 1194) and OmniExpress (N= 1656) were used
for genotyping the control samples.
Genotype imputation was performed using the Michigan imputation server
(https://imputationserver.sph.umich.edu/index.html#!pages/home) with the 1000
Genome dataset (phase3 v5 release) of East Asians as a reference panel for each
dataset. In each dataset, SNPs with a call rate <90% or a minor allele frequency <1%
were excluded before genotype imputation. Imputed SNPs for which R2 was <0.9
were excluded from the subsequent association analysis. Next, SNPs with a call rate
<90%, a minor allele frequency <1%, or significant deviation (P < 1.0 × 10−5) from
Hardy–Weinberg equilibrium were excluded from further statistical analysis, and
samples with a call rate <90% were also excluded. We checked the allelic
discrimination of SNPs showing a suggestive association with CSC in the discovery
GWAS (P < 1.0 × 10−5) for each platform. We excluded SNPs with an insufficient
quality of allelic discrimination and their proxy SNPs (R2 > 0.8). Finally, 2,893,743
SNPs from 610 CSC samples and 2850 control samples were used for discovery
stage analysis.
In the first replication stage, genotypes of CSC samples (N= 278) were
determined using a commercially available assay (TaqMan SNP assay with the ABI
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PRISM 7700 system; Applied Biosystems, Foster City, CA, USA). We extracted the
allele frequency from existing healthy Japanese genome-wide datasets, which
included the Tohoku dataset54–56, Kyoto University57,58, and Yokohama City
University datasets. The details of the genotyping methods are summarized in
the Supplementary Note. Briefly, the Integrative Japanese Genome Variation
Database (ver 3.5 K JPN, https://ijgvd.megabank.tohoku.ac.jp/) provides genomic
reference panels obtained from 3554 normal Japanese subjects recruited from the
Tohoku Medical Megabank Organization, Iwate Medical Megabank Organization,
Nagahama Prospective Cohort for Comprehensive Human Bioscience, and
National Hospital Organization Nagasaki Medical Center. All DNA samples were
whole-genome-sequenced using the Illumina HiSeq 2500. The Human Genetic
Variation Database is a database of genomic reference panels released from Kyoto
University (http://www.hgvd.genome.med.kyoto-u.ac.jp/index.html). This database
is a web-accessible resource of genetic variations in the Japanese population.
Whole-genome SNV genotyping was performed for 3712 individuals, who formed
a subset of participants of The Nagahama Prospective Genome Cohort for the
Comprehensive Human Bioscience (the Nagahama Study), with the Illumina
HumanHap610 quad, Omni 2.5 M and Human exome Beadarrays (Illumina). The
Yokohama City University dataset includes 1048 Japanese healthy controls
recruited from the Yokohama City University, Okada Eye Clinic, and Aoto Eye
Clinic in Yokohama, Kanagawa Prefecture, Japan. Genotypes of samples from
Yokohama City University were determined using BeadChip DNA arrays, namely
Human OmniExpress chip (Illumina), with the standard protocol recommended
by each manufacturer.
The Kobe CSC case–control dataset, which was used in the second replication
stage, was genotyped using the Human OmniExpress BeadChips (Illumina, San
Diego, CA, USA) as described elsewhere31. Genomic imputation was performed for
the dataset using the BEAGLE 4.1 and 1000 genomes dataset (phase3 v5 release) as
the reference panels. Imputed SNPs for which R2 < 0.7 were excluded from the
imputed dataset. The association of SNPs with CSC was tested by logistic
regression analysis with no adjustment. The European CSC case–control dataset,
which was used in the third replication stage, was genotyped using OmniExpress-
12 or OmniExpress-24chip. The data were imputed with the Haplotype Reference
Consortium release 1.1.2016, and were stringent quality controls were performed as
described previously30.
Statistical analyses. Genome-wide logistic regression analysis was conducted for
the CSC, adjusting for three principal components. As on age and sex was not
available for 1656 out of the 2850 control samples, adjustment for these factors was
not performed in the discovery GWAS. Experiment-wide significance in the dis-
covery stage was set to P= 5.0 × 10−8. We carried SNPs with P-value of <1.0 × 10−6
forward to the replication stage. In the first and second replication stages, logistic
regression was performed for the SNPs that showed suggestive association in the
first-stage. All meta-analyses were performed using the fixed-effect model. There-
after, differences were considered significant at P < 0.05. Deviations in genotype
distributions from Hardy–Weinberg equilibrium were assessed with chi-square
tests. These statistical analyses were performed with R ver 3.5.2 (R Foundation for
Statistical Computing, Vienna, Austria; available at http://www.rproject.org/),
GCTA ver. 1.25.3 (http://cnsgenomics.com/software/gcta/index.html#Overview)
and PLINK ver. 2.0 (https://www.cog-genomics.org/plink/2.0/).
In the third replication stage using the European dataset, association analysis
was performed using the Firth bias-corrected likelihood ratio test, implemented in
EPACTS (version 3.2.6, https://genome.sph.umich.edu/wiki/EPACTS; University
of Michigan), correcting for sex and the first two components of ancestry analysis.
Pathway analysis. Using the GWAS summary statistics and P-values of replicated
SNPs, we performed gene-based analysis and clustered genes into pathways using
VEGAS2pathway (https://vegas2.qimrberghofer.edu.au/, version 2). Briefly,
VEGAS2 successively prunes the list of variants with R2 criteria of 0.99, 0.90, 0.70,
and 0.50, if a gene contains >1000 SNPs. After each pruning interval, VEGAS2
checks the number of pruned SNPs. If the number of pruned SNPs is <1000,
VEGAS2 uses the pruned SNPs from that interval to perform gene-based analysis;
otherwise, it iteratively applies an increasingly stringent R2 criteria on all SNPs in
the gene. After applying a pruning criterion of R2= 0.50, it uses all pruned SNPs for
analysis irrespective of the number. The gene list was obtained from the VEGAS2
official site (https://vegas2.qimrberghofer.edu.au/glist-hg19). Obtained gene-based
result was used to perform calculate pathway-based tests and empirical P-values to
obtain the significance of each pathway. Regions +/− 0 kb outside of genes were
defined as gene regions, and all SNPs were used for analysis. For the SNPs that were
carried forward for to the replication stage, P-values from meta-analysis were used
rather than GWAS P-values. The Biosystems gene-pathway annotation file was
obtained from the VEGAS2 official site (https://vegas2.qimrberghofer.edu.au/
biosystems20160324.vegas2pathSYM). The significance threshold of the empirical
P-value in the pathway analysis was set to 1.0 × 10−530,35.
Database search. To determine the existence of a population substructure and
its influence on the GWAS results, publicly available genotype data from five
populations, including African, South Asian, European, East Asian, and Japanese
(1000 Genome project, Phase 3, ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/
20130502/) were used for PCA.
Searching of the publicly available quantitative trait locus analysis (eQTL)
database (Genotype-Tissue Expression (GTEx) Portal: https://gtexportal.org/home/)
revealed an association between the SNP genotypes and gene expression in multiple
human tissues. NES is defined as the slope of the linear regression and is computed
as the effect of the alternative allele relative to the reference allele.
Expression of genes in the adult human retina and RPE was explored in the
eyeintegration database (https://eyeintegration.nei.nih.gov/, v1.01. accessed 10
April 2019). The database lists the expression levels of genes given in transcripts
per million. Gene expression levels were compared by Wilcoxon test. Expression of
genes in the human retina and choroid was explored in The OCULAR TISSUE
DATABASE (https://genome.uiowa.edu/otdb/, accessed 28 February 2019). This
database provides quantitative expression level of genes in ocular tissues
determined by the PLIER (Probe Logarithmic Intensity Error) algorithm.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Top SNPs (n= 100) in the discovery GWAS can be available as Supplementary Data 1.
The source data about the expression of genes in the adult human retina and RPE can be
available as Supplementary Data 2. The complete GWAS summary data can be visualized
here: https://figshare.com/articles/CSC_control_PC3_assoc_logistic/11136047. The
datasets generated during the current study are also available from the corresponding
author on reasonable request.
Received: 19 June 2019; Accepted: 26 November 2019;
References
1. Gemenetzi, M., De Salvo, G. & Lotery, A. J. Central serous chorioretinopathy:
an update on pathogenesis and treatment. Eye 24, 1743–1756 (2010).
2. Kitzmann, A. S., Pulido, J. S., Diehl, N. N., Hodge, D. O. & Burke, J. P. The
incidence of central serous chorioretinopathy in Olmsted county, Minnesota,
1980-2002. Ophthalmology 115, 169–173 (2008).
3. Nicholson, B., Noble, J., Forooghian, F. & Meyerle, C. Central serous
chorioretinopathy: update on pathophysiology and treatment. Surv.
Ophthalmol. 58, 103–126 (2013).
4. Bujarborua, D. Long-term follow-up of idiopathic central serous
chorioretinopathy without laser. Acta Ophthalmol. Scand. 79, 417–421 (2001).
5. Breukink, M. B. et al. Chronic central serous chorioretinopathy: long-term
follow-up and vision-related quality of life. Clin. Ophthalmol. 11, 39–46 (2016).
6. Mrejen, S. et al. Long-term visual outcomes and causes of vision loss in
chronic central serous chorioretinopathy. Ophthalmology https://doi.org/
10.1016/j.ophtha.2018.12.048 (2019).
7. Shiragami, C. et al. Clinical features of central serous chorioretinopathy with
Type 1 choroidal neovascularization. Am. J. Ophthalmol. 193, 80–86 (2018).
8. Daruich, A. et al. Central serous chorioretinopathy: recent findings and new
physiopathology hypothesis. Prog. Retin. Eye Res. 48, 82–118 (2015).
9. Yannuzzi, L. Type-A behavior and central serous chorioretinopathy. Retina
7:2, 111–131 (1987).
10. Haimovici, R., Koh, S., Gagnon, D. R., Lehrfeld, T. & Wellik, S. Risk factors for
central serous chorioretinopathy: a case-control study. Ophthalmology 111,
244–249 (2004).
11. Weenink, A. A. C., Borsje, R. A. & Oosterhuis, J. A. J. A. Familial chronic
central serous chorioretinopathy. Ophthalmologica 215, 183–187 (2001).
12. Mateo-Montoya, A. & Mauget-Faÿse, M. Helicobacter pylori as a risk factor
for central serous chorioretinopathy: literature review. World J. Gastrointest.
Pathophysiol. 5, 355–358 (2014).
13. Bagheri, M., Rashe, Z., Ahoor, M. H. & Somi, M. H. Prevalence of
Helicobacter pylori infection in patients with central serous chorioretinopathy:
a review. Med. hypothesis, Discov. Innov. Ophthalmol. J. 6, 118–124 (2017).
14. Zavoloka, O. Helicobacter pylori is the culprit behind central serous
chorioretinopathy. Graefe’s Arch. Clin. Exp. Ophthalmol. 254, 2071 (2016).
15. Wang, M. et al. Central serous chorioretinopathy. Acta Ophthalmol. 86,
126–145 (2008).
16. Spaide, R. F. et al. Central serous chorioretinopathy in younger and older
adults. Ophthalmology 103, 2070–2080 (1996).
17. Pang, C. E. & Freund, K. B. Pachychoroid neovasculopathy. Retina 35, 1–9
(2015).
18. Lehmann, M., Bousquet, E., Beydoun, T. & Behar-Cohen, F. Pachychoroid: an
inherited condition? Retina 35, 10–16 (2015).
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-019-0712-z ARTICLE
COMMUNICATIONS BIOLOGY |           (2019) 2:468 | https://doi.org/10.1038/s42003-019-0712-z | www.nature.com/commsbio 7
19. Miyake, M. et al. Pachychoroid neovasculopathy and age-related macular
degeneration. Sci. Rep. 5, 16204 (2015).
20. Fung, A. T., Yannuzzi, L. A. & Bailey Freund, K. Type 1 (Sub-retinal pigment
epithelial) neovascularization in central serous chorioretinopathy
masquerading as neovascular age-related macular degeneration. Retina 32,
1829–1837 (2012).
21. Azar, G. et al. Pachychoroid neovasculopathy: aspect on optical coherence
tomography angiography. Acta Ophthalmol. 95, 421–427 (2017).
22. Cheung, C. M. G. et al. Pachychoroid disease. Eye 33, 14–33 (2019).
23. Gallego-Pinazo, R., Dolz-Marco, R. & Freund, K. B. in Choroidal Disorders.
161–170 (Academic Press, 2017).
24. Hata, M. et al. Intraocular vascular endothelial growth factor levels in
pachychoroid neovasculopathy and neovascular age- related macular
degeneration. Investig. Ophthalmol. Vis. Sci. 58, 292–298 (2017).
25. Akkaya, S. Spectrum of pachychoroid diseases. Int. Ophthalmol. 1–8, https://
doi.org/10.1007/s10792-017-0666-4 (2017).
26. Klein, R. J., Robert, J., Emily, Y. & Tsai, J. Complement factor H polymorphism
in age-related macular degeneration. Sci. (80−.). 308, 385–389 (2005).
27. Miki, A. et al. Common variants in the complement factor H gene confer
genetic susceptibility to central serous chorioretinopathy. Ophthalmology 121,
1067–1072 (2014).
28. Hosoda, Y. et al. CFH and VIPR2 as susceptibility loci in choroidal thickness
and pachychoroid disease central serous chorioretinopathy. Proc. Natl Acad.
Sci. USA 115, 6261–6266 (2018).
29. De Jong, E. K. et al. Chronic central serous chorioretinopathy is associated
with genetic variants implicated in age-related macular degeneration.
Ophthalmology 122, 562–570 (2015).
30. Schellevis, R. L. et al. Role of the complement system in chronic central serous
chorioretinopathy: a genome-wide association study. JAMA Ophthalmol.
https://doi.org/10.1001/jamaophthalmol.2018.3190 (2018).
31. Miki, A. et al. Genome-wide association study to identify a new susceptibility
locus for central serous chorioretinopathy in the Japanese population. Investig.
Opthalmol. Vis. Sci. 59, 5542 (2018).
32. Dijk, E. et al. Association of a haplotype in the NR3C2 gene, encoding the
mineralocorticoid receptor, with chronic central serous chorioretinopathy.
Ophthalmology 135, 446–451 (2017).
33. Mohabati, D. et al. Genetic risk factors in acute central serous chorioretinopathy.
Retina 1, https://doi.org/10.1097/IAE.0000000000002333 (2018).
34. Breukink, M. B. et al. Genomic copy number variations of the complement
component C4B Ggene are associated with chronic central serous
chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 56, 5608–5613 (2015).
35. Mishra, A. & MacGregor, S. A novel approach for pathway analysis of GWAS
data highlights role of BMP signaling and muscle cell differentiation in
colorectal cancer susceptibility. Twin Res. Hum. Genet. 20, 1–9 (2017).
36. Arakawa, S. et al. Genome-wide association study identifies two susceptibility
loci for exudative age-related macular degeneration in the Japanese
population. Nat. Genet. 43, 1001–1005 (2011).
37. Fritsche, L. G. et al. Seven new loci associated with age-related macular
degeneration. Nat. Genet. 45, 433–439 (2013).
38. Sun, Y. et al. TNFRSF10A-LOC389641 rs13278062 but not REST-C4orf14-
POLR2B-IGFBP7 rs1713985 was found associated with age-related macular
degeneration in a Chinese population. Invest. Ophthalmol. Vis. Sci. 54,
8199–8203 (2013).
39. Fritsche, L. G. et al. A large genome-wide association study of age-related
macular degeneration highlights contributions of rare and common variants.
Nat. Genet. 48, 134–143 (2016).
40. Cheung, C. M. G. et al. Association between choroidal thickness and drusen
subtypes in age-related macular degeneration. Ophthalmol. Retin. 2,
1196–1205 (2018).
41. Gass, J. D. M. & Little, H. Bilateral bullous exudative retinal detachment
complicating idiopathic central serous chorioretinopathy during systemic
corticosteroid therapy. Ophthalmology 102, 737–747 (1995).
42. Bouzas, E. A., Karadimas, P. & Pournaras, C. J. Central serous
chorioretinopathy and glucocorticoids. Surv. Ophthalmol. 47, 431–448 (2002).
43. Jiang, J. -Q. et al. Prevalence and spectrum of GATA5 mutations associated
with congenital heart disease. Int. J. Cardiol. 165, 570–573 (2013).
44. Stennard, F. A. et al. Cardiac T-box factor Tbx20 directly interacts with Nkx2-
5, GATA4, and GATA5 in regulation of gene expression in the developing
heart. Dev. Biol. 262, 206–224 (2003).
45. Reiter, J. F. et al. Gata5 is required for the development of the heart and
endoderm in zebrafish. Genes Dev. 13, 2983–2995 (1999).
46. Messaoudi, S. et al. Endothelial Gata5 transcription factor regulates blood
pressure. Nat. Commun. 6, 8835 (2015).
47. Cakir, B. et al. OCT Angiography of the choriocapillaris in central serous
chorioretinopathy: a quantitative subgroup analysis. Ophthalmol. Ther.
https://doi.org/10.1007/s40123-018-0159-1 (2019).
48. Rochepeau, C. et al. Optical coherence tomography angiography quantitative
assessment of choriocapillaris blood flow in central serous chorioretinopathy.
Am. J. Ophthalmol. 194, 26–34 (2018).
49. Wang, X. et al. Epigenetic subgroups of esophageal and gastric
adenocarcinoma with differential GATA5 DNA methylation associated with
clinical and lifestyle factors. PLoS ONE https://doi.org/10.1371/journal.
pone.0025985 (2011).
50. Sobota, R. S. et al. Epigenetic and genetic variation in GATA5 is associated
with gastric disease risk. Hum. Genet. 8, 895–906 (2016).
51. Fukuda, K. & Yasugi, S. The molecular mechanisms of stomach development
in vertebrates. Dev. Growth Differ. 6, 375–382 (2005).
52. Wen, X. Z. et al. Methylation of GATA-4 and GATA-5 and development of
sporadic gastric carcinomas. World J. Gastroenterol. 16, 1201–1208 (2010).
53. Aung, T. et al. A common variant mapping to CACNA1A is associated with
susceptibility to exfoliation syndrome. Nat. Genet. 47(Apr), 387–392 (2015).
54. Kuriyama, S. et al. The Tohoku medical megabank project: design and
mission. J. Epidemiol. 26, 493–511 (2016).
55. Yamaguchi-Kabata, Y. et al. iJGVD: an integrative Japanese genome variation
database based on whole-genome sequencing. Hum. Genome Var. 2, 15050
(2015).
56. Nagasaki, M. et al. Rare variant discovery by deep whole-genome sequencing
of 1,070 Japanese individuals. Nat. Commun. 6, 8018 (2015).
57. Narahara, M. et al. Large-scale East-Asian eQTL mapping reveals novel
candidate genes for LD mapping and the genomic landscape of transcriptional
effects of sequence variants. PLoS ONE 9, e100924 (2014).
58. Higasa, K. et al. Human genetic variation database, a reference database of
genetic variations in the Japanese population. J. Hum. Genet. 61, 547–553
(2016).
Acknowledgements
We thank Ms. Hatsue Hamanaka for assistance with genotyping. We thank for Dr.
Masato Akiyama for supervising about method of the pathway analysis.
Author contributions
Y.H., M.M., R.Y., F.M., K.Y., and A.T. designed the study; Y.H., M.M., R.L.S., C.J.F.B.,
C.B.H., A.Mi., A.Me., Y.S., S.Y., Y.T., M.H., Y.M., H.N., A.O., S.O., H.T., A.U., M.M.,
A.Tak., N.U.A., A.Taj., T.S., N.M., C.S., T.I., S.H., E.K.D.J., A.I.D.H., K.Y., and A.T.
performed the study; Y.H., M.M., R.L.S., C.J.F.B., C.B.H., A.Mi., A.Me., A.Tak., T.S.,
N.M., C.C.K., T.Y.W., R.Y., S.H., E.K.D.J., A.I.D.H., K.Y., and A.Taj. analyzed the data;
and Y.H., M.M., and K.Y. prepared the manuscript.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s42003-
019-0712-z.
Correspondence and requests for materials should be addressed to M.M.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-019-0712-z
8 COMMUNICATIONS BIOLOGY |           (2019) 2:468 | https://doi.org/10.1038/s42003-019-0712-z | www.nature.com/commsbio
Yoshikatsu Hosoda1,2, Masahiro Miyake1,2*, Rosa L. Schellevis3, Camiel J.F. Boon4, Carel B. Hoyng3, Akiko Miki5,
Akira Meguro6, Yoichi Sakurada7, Seigo Yoneyama7, Yukari Takasago8, Masayuki Hata1, Yuki Muraoka1,
Hideo Nakanishi1, Akio Oishi 1, Sotaro Ooto1, Hiroshi Tamura 1, Akihito Uji1, Manabu Miyata 1,
Ayako Takahashi1, Naoko Ueda-Arakawa1, Atsushi Tajima 9, Takehiro Sato 9, Nobuhisa Mizuki6,
Chieko Shiragami 8, Tomohiro Iida10, Chiea Chuen Khor 11,12, Tien Yin Wong11,13,14, Ryo Yamada2,
Shigeru Honda5,15, Eiko K. de Jong 3, Anneke I. den Hollander 3, Fumihiko Matsuda2,
Kenji Yamashiro 1,16,17 & Akitaka Tsujikawa1,17
1Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan. 2Center for Genomic Medicine,
Kyoto University Graduate School of Medicine, Kyoto, Japan. 3Department of Ophthalmology, Donders Institute of Brain, Cognition and Behaviour,
Radboud University Medical Centre, Nijmegen, The Netherlands. 4Department of Ophthalmology, Leiden University Medical Center, Leiden, The
Netherlands. 5Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan. 6Department of
Ophthalmology and Visual Sciences, Yokohama City University School of Medicine, Yokohama, Japan. 7Department of Ophthalmology, University
of Yamanashi, Faculty of Medicine, Yamanashi, Japan. 8Department of Ophthalmology, Kagawa University Faculty of Medicine, Kagawa, Japan.
9Department of Bioinformatics and Genomics, Graduate School of Advanced Preventive Medical Sciences, Kanazawa University, Kanazawa,
Ishikawa, Japan. 10Department of Ophthalmology, Tokyo Women’s Medical University, Tokyo, Japan. 11Singapore National Eye Centre, Singapore
Eye Research Institute, Singapore, Singapore. 12Division of Human Genetics, Genome Institute of Singapore, Singapore, Singapore. 13Saw Swee Hock
School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore. 14Ophthalmology and Visual
Sciences Academic Clinical Program, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore. 15Department of
Ophthalmology and Visual Sciences, Osaka City University Graduate School of Medicine, Osaka, Japan. 16Department of Ophthalmology, Otsu Red-
Cross Hospital, Otsu, Japan. 17These authors contributed equally: Kenji Yamashiro, Akitaka Tsujikawa. *email: miyakem@kuhp.kyoto-u.ac.jp
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-019-0712-z ARTICLE
COMMUNICATIONS BIOLOGY |           (2019) 2:468 | https://doi.org/10.1038/s42003-019-0712-z | www.nature.com/commsbio 9
